Adage Capital Partners’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.8M | Buy |
282,436
+49,600
| +21% | +$4.39M | 0.05% | 374 |
|
|
2025
Q4 | $20.3M | Sell |
232,836
-485,366
| -68% | -$39.7M | 0.03% | 479 |
|
|
2025
Q3 | $47.7M | Sell |
718,202
-374,060
| -34% | -$21.3M | 0.08% | 248 |
|
|
2025
Q2 | $60.4M | Buy |
1,092,262
+748,758
| +218% | +$35.9M | 0.1% | 193 |
|
|
2025
Q1 | $16.6M | Buy |
+343,504
| New | +$14.4M | 0.03% | 465 |
|
|
2024
Q4 | – | Sell |
-1,200,891
| Closed | -$54M | – | 944 |
|
|
2024
Q3 | $54M | Sell |
1,200,891
-800,451
| -40% | -$32.3M | 0.1% | 218 |
|
|
2024
Q2 | $69.3M | Sell |
2,001,342
-217,526
| -10% | -$6.37M | 0.13% | 167 |
|
|
2024
Q1 | $64.2M | Buy |
2,218,868
+927,167
| +72% | +$25.2M | 0.12% | 184 |
|
|
2023
Q4 | $29.6M | Buy |
1,291,701
+591,701
| +85% | +$10.4M | 0.06% | 322 |
|
|
2023
Q3 | $11.7M | Sell |
700,000
-592,711
| -46% | -$11.5M | 0.03% | 531 |
|
|
2023
Q2 | $35.7M | Sell |
1,292,711
-1,265,289
| -49% | -$31.7M | 0.08% | 261 |
|
|
2023
Q1 | $58.8M | Buy |
2,558,000
+1,790,955
| +233% | +$30.1M | 0.13% | 180 |
|
|
2022
Q4 | $8.37M | Sell |
767,045
-106,000
| -12% | -$894K | 0.02% | 673 |
|
|
2022
Q3 | $7.36M | Sell |
873,045
-127,000
| -13% | -$1.2M | 0.02% | 717 |
|
|
2022
Q2 | $7.91M | Buy |
1,000,045
+400,000
| +67% | +$4.84M | 0.02% | 729 |
|
|
2022
Q1 | $14.2M | Buy |
600,045
+150,000
| +33% | +$4.23M | 0.03% | 597 |
|
|
2021
Q4 | $15.4M | Buy |
450,045
+150,000
| +50% | +$4.74M | 0.03% | 572 |
|
|
2021
Q3 | $5.32M | Sell |
300,045
-250,000
| -45% | -$10.7M | 0.01% | 825 |
|
|
2021
Q2 | $24.7M | Sell |
550,045
-50,000
| -8% | -$1.65M | 0.05% | 386 |
|
|
2021
Q1 | $15.5M | Sell |
600,045
-550,000
| -48% | -$13.9M | 0.03% | 542 |
|
|
2020
Q4 | $23.2M | Sell |
1,150,045
-1,370,555
| -54% | -$29.5M | 0.05% | 383 |
|
|
2020
Q3 | $49.3M | Buy |
2,520,600
+320,600
| +15% | +$6.02M | 0.12% | 181 |
|
|
2020
Q2 | $38.9M | Buy |
+2,200,000
| New | +$27.6M | 0.1% | 231 |
|
|
2018
Q3 | – | Sell |
-500,000
| Closed | -$3.36M | – | 749 |
|
|
2018
Q2 | $3.36M | Sell |
500,000
-500,000
| -50% | -$3.84M | 0.01% | 675 |
|
|
2018
Q1 | $8.59M | Sell |
1,000,000
-1,056,076
| -51% | -$19.9M | 0.02% | 583 |
|
|
2017
Q4 | $42.8M | Hold |
2,056,076
| – | – | 0.1% | 253 |
|
|
2017
Q3 | $36.3M | Hold |
2,056,076
| – | – | 0.09% | 282 |
|
|
2017
Q2 | $23.3M | Buy |
2,056,076
+400,000
| +24% | +$4.28M | 0.06% | 383 |
|
|
2017
Q1 | $21.2M | Buy |
1,656,076
+125,000
| +8% | +$2.01M | 0.05% | 388 |
|
|
2016
Q4 | $33.7M | Sell |
1,531,076
-50,000
| -3% | -$1.11M | 0.09% | 273 |
|
|
2016
Q3 | $33.4M | Buy |
+1,581,076
| New | +$21.6M | 0.09% | 291 |
|
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
Adage Capital Partners's PTGX Position: Q1 2026 in Review
Adage Capital Partners increased its Protagonist Therapeutics (PTGX) stake by 21% in Q1 2026, buying an estimated $4.39M and bringing the position to 282,436 shares worth $29.8M. The position accounts for 0.05% of the portfolio, ranked #374.
Adage Capital Partners first reported a position in PTGX in Q3 2016 and has held it in 31 quarters since. The position peaked at $69.3M in Q2 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- Adage Capital Partners held 282,436 shares of Protagonist Therapeutics worth $29.8M as of Q1 2026.
- Adage Capital Partners bought 49,600 Protagonist Therapeutics shares in Q1 2026, an estimated $4.39M.
- Protagonist Therapeutics made up 0.05% of Adage Capital Partners's portfolio in Q1 2026, its #374 holding.
- Adage Capital Partners first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 31 quarters since.
- Adage Capital Partners's Protagonist Therapeutics position peaked at $69.3M in Q2 2024.
- 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.